MicuRx(SH:688373) Mei Ri Jing Ji Xin Wen·2026-01-20 10:57Core Viewpoint - The company reported a revenue growth of 6.58% year-on-year for the first three quarters of 2025, indicating a slowdown in growth rate compared to previous periods [2] Group 1: Revenue and Growth - The company's revenue for the first three quarters of 2025 reached 104 million yuan, reflecting a modest increase in sales volume and revenue compared to the same period last year [2] - The growth rate of 6.58% is significantly lower than previous growth rates, raising questions about the factors contributing to this slowdown [2] Group 2: Product Development and Clinical Trials - As of mid-2025, the company's drug, 康替唑胺片, has been adopted by 580 hospitals nationwide, with 180 hospitals achieving formal access and bulk procurement [2] - The company initiated a Phase II clinical trial in April 2023 for the oral formulation of 康替唑胺片 targeting complex skin and soft tissue infections in patients aged 6 to 17, which is currently ongoing [2] - Additional clinical trials for other drugs, including MRX-4, MRX-8, and MRX-5, are progressing, with MRX-4 receiving NDA acceptance in May 2025 for treating complex skin and soft tissue infections [2]